Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
UMC Utrecht
University of Colorado, Denver
City of Hope Medical Center
Barbara Ann Karmanos Cancer Institute
University of Nebraska
Natera, Inc.
Novartis
Var2 Pharmaceuticals
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
A2 Biotherapeutics Inc.
University of California, San Francisco
ModeX Therapeutics, An OPKO Health Company
Columbia University
University of Arizona
Tempus AI
Esperas Pharma Inc.
Instituto de Investigacion Sanitaria La Fe
Stanford University
Stanford University
Taproot Health
Northwestern University
Hutchmed
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chongqing Precision Biotech Co., Ltd
National Cancer Institute (NCI)
Corvus Pharmaceuticals, Inc.
Chongqing Precision Biotech Co., Ltd
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Klus Pharma Inc.
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Qianfoshan Hospital
Institut de Cancérologie de Lorraine
Uppsala University
University of Southern Denmark
Weprom
Novartis
MacroGenics
Ohio State University Comprehensive Cancer Center
Wake Forest University Health Sciences
Gilead Sciences
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
Institut Bergonié
Abramson Cancer Center at Penn Medicine